We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
ImmuCell Reports Y/Y Q1 Earnings Growth on Record Sales & Margin Gains
Read MoreHide Full Article
Shares of ImmuCell Corporation (ICCC - Free Report) have gained 3.9% since reporting results for the first quarter of 2025. This compares with the S&P 500 index’s 5.5% rise over the same time frame. Over the past month, the stock has jumped 11.2% against the S&P 500’s 13.5% rally.
Revenue & Earnings Surge
ImmuCell posted a strong financial performance for the first quarter of 2025, delivering a record $8.1 million in product sales, up 11% from $7.3 million in the prior-year period. The rise marked a continuation of momentum established in late 2024. Net income turned positive to $1.45 million from a net loss of $438,000 in the same quarter a year ago. This swing was driven by sales growth and gross margin expansion. Earnings per share improved to 16 cents from a loss of 6 cents per share in the prior-year quarter.
ImmuCell Corporation Price, Consensus and EPS Surprise
The gross margin for the quarter improved to 42% from 37% in the fourth quarter of 2024, and is significantly higher than the margin reported a year ago when the company faced elevated scrap and contamination-related costs. This progress reflects operational normalization following production disruptions in 2022 and 2023.
Adjusted EBITDA for the first quarter came in at $2.3 million, a sharp rise from $458,000 in the prior-year quarter. For the trailing 12 months ended March 31, 2025, adjusted EBITDA totaled $3.3 million, up from a $280,000 loss in the comparable period.
First Defense — ImmuCell’s flagship product line for scours prevention in calves — accounted for the majority of sales. Tri-Shield, which contains E. coli, coronavirus and rotavirus claims, represented 71% of First Defense product sales for the quarter. Management noted that expanded capacity and the diversification of delivery formats, including gel tubes and a soon-to-launch bulk powder product, are improving customer reach and supporting revenue growth.
Management Commentary
CEO Michael Brigham emphasized that the business has become larger, more complex and increasingly diversified, driven primarily by the strength of First Defense and continued investment in production capacity. The company’s annualized manufacturing capacity has been scaled to support $30 million in sales. Brigham also noted that contamination issues that affected the prior quarters have been successfully remediated, with no new events since April 2024.
New CFO Tim Fiori highlighted cost control and operational improvements, particularly in managing fixed costs across higher sales volumes. He also mentioned that gross margin expansion and improved adjusted EBITDA are the key to driving long-term profitability, especially with many fixed facility and labor costs already in place.
Factors Influencing the Headline Numbers
The turnaround in profitability and margins stems from a combination of operational stability, capacity expansion and higher sales volumes. Past contamination events had led to increased scrap costs and disrupted inventory flow.
However, the company has operated without further contamination incidents for over a year, allowing for better yields and manufacturing efficiencies. Additionally, customer demand for Tri-Shield has risen sharply, reflecting the product’s strong efficacy claims compared with traditional dam-level vaccines.
Sales were also buoyed by improved distribution and a strengthened sales team that includes four regional managers, a commercial stakeholder leader, and a marketing director. The backlog of orders, which had accumulated during supply disruptions, has been gradually reduced, standing at $4 million as of March 31 and falling further to $3.4 million by early May.
Guidance
ImmuCell stated that its backlog reduction and increased production capability position it well for continued sales growth. The company expects the recently introduced investigational product use of Re-Tain to yield valuable field feedback, which could help shape future commercialization strategies. Brigham acknowledged that while full FDA approval for Re-Tain remains pending due to manufacturing inspection delays, the investigational phase will allow for data collection on product performance in real-world settings.
Other Developments
The company confirmed that it paused a $4-million investment to bring formulation and aseptic filling for Re-Tain in-house. This initiative may resume once further clarity is achieved regarding FDA licensing timelines and strategic options.
Overall, ImmuCell’s first-quarter performance demonstrated solid operational recovery and financial improvement, driven by sustained demand for its core products and improved execution following prior-year setbacks.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
ImmuCell Reports Y/Y Q1 Earnings Growth on Record Sales & Margin Gains
Shares of ImmuCell Corporation (ICCC - Free Report) have gained 3.9% since reporting results for the first quarter of 2025. This compares with the S&P 500 index’s 5.5% rise over the same time frame. Over the past month, the stock has jumped 11.2% against the S&P 500’s 13.5% rally.
Revenue & Earnings Surge
ImmuCell posted a strong financial performance for the first quarter of 2025, delivering a record $8.1 million in product sales, up 11% from $7.3 million in the prior-year period. The rise marked a continuation of momentum established in late 2024. Net income turned positive to $1.45 million from a net loss of $438,000 in the same quarter a year ago. This swing was driven by sales growth and gross margin expansion. Earnings per share improved to 16 cents from a loss of 6 cents per share in the prior-year quarter.
ImmuCell Corporation Price, Consensus and EPS Surprise
ImmuCell Corporation price-consensus-eps-surprise-chart | ImmuCell Corporation Quote
Other Key Business Metrics
The gross margin for the quarter improved to 42% from 37% in the fourth quarter of 2024, and is significantly higher than the margin reported a year ago when the company faced elevated scrap and contamination-related costs. This progress reflects operational normalization following production disruptions in 2022 and 2023.
Adjusted EBITDA for the first quarter came in at $2.3 million, a sharp rise from $458,000 in the prior-year quarter. For the trailing 12 months ended March 31, 2025, adjusted EBITDA totaled $3.3 million, up from a $280,000 loss in the comparable period.
First Defense — ImmuCell’s flagship product line for scours prevention in calves — accounted for the majority of sales. Tri-Shield, which contains E. coli, coronavirus and rotavirus claims, represented 71% of First Defense product sales for the quarter. Management noted that expanded capacity and the diversification of delivery formats, including gel tubes and a soon-to-launch bulk powder product, are improving customer reach and supporting revenue growth.
Management Commentary
CEO Michael Brigham emphasized that the business has become larger, more complex and increasingly diversified, driven primarily by the strength of First Defense and continued investment in production capacity. The company’s annualized manufacturing capacity has been scaled to support $30 million in sales. Brigham also noted that contamination issues that affected the prior quarters have been successfully remediated, with no new events since April 2024.
New CFO Tim Fiori highlighted cost control and operational improvements, particularly in managing fixed costs across higher sales volumes. He also mentioned that gross margin expansion and improved adjusted EBITDA are the key to driving long-term profitability, especially with many fixed facility and labor costs already in place.
Factors Influencing the Headline Numbers
The turnaround in profitability and margins stems from a combination of operational stability, capacity expansion and higher sales volumes. Past contamination events had led to increased scrap costs and disrupted inventory flow.
However, the company has operated without further contamination incidents for over a year, allowing for better yields and manufacturing efficiencies. Additionally, customer demand for Tri-Shield has risen sharply, reflecting the product’s strong efficacy claims compared with traditional dam-level vaccines.
Sales were also buoyed by improved distribution and a strengthened sales team that includes four regional managers, a commercial stakeholder leader, and a marketing director. The backlog of orders, which had accumulated during supply disruptions, has been gradually reduced, standing at $4 million as of March 31 and falling further to $3.4 million by early May.
Guidance
ImmuCell stated that its backlog reduction and increased production capability position it well for continued sales growth. The company expects the recently introduced investigational product use of Re-Tain to yield valuable field feedback, which could help shape future commercialization strategies. Brigham acknowledged that while full FDA approval for Re-Tain remains pending due to manufacturing inspection delays, the investigational phase will allow for data collection on product performance in real-world settings.
Other Developments
The company confirmed that it paused a $4-million investment to bring formulation and aseptic filling for Re-Tain in-house. This initiative may resume once further clarity is achieved regarding FDA licensing timelines and strategic options.
Overall, ImmuCell’s first-quarter performance demonstrated solid operational recovery and financial improvement, driven by sustained demand for its core products and improved execution following prior-year setbacks.